Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

C3 Summit London
May 5, 2025
We’re pleased to share that Mo Yaqoob from our Business Development team will be attending the C3 Summit on 8 May 2025 at 8 Northumberland Ave, London. 🔗 https://www.thec3summit.com/london-2025/  Mo is looking forward to meeting fellow attendees, exploring new partnerships, and discussing how we can work together to accelerate the development of innovative drug candidates. If you're attending, don’t hesitate to connect let’s spark the next great collaboration!
April 30, 2025
We’re excited to share that Ash Alavijeh , our Head of Operations, will attend the Swiss Biotech Day 2025 on May 5–6 at the Congress Center Basel, Switzerland! 🔗 https://swissbiotechday.ch Ash looks forward to connecting with attendees to explore new collaborations and drive drug discovery and development forward. If you're in Basel, let's meet and discuss how we can advance the next wave of innovative therapies together.
April 28, 2025
We are pleased to announce that Martin Barrett , our Head of Business Development, will be attending the Making & Distributing Pharmaceuticals UK event on 29–30 April 2025 at the Coventry Building Society Arena! 🔗 ( https://lnkd.in/gd73pvE ) Martin would be delighted to meet with fellow attendees to discuss new collaboration opportunities and how we can work together to advance the development of innovative drug candidates. If you are attending, don’t miss the chance to connect with us and explore how we can drive pharmaceutical progress forward together!
More Posts